Abstract:Background A retrospective utilization study was performed to evaluate utilization patterns for enteral nutrition in a university teaching hospital. Methods Enteral nutrition was divided into three types according to the nitrogen source, ie, total protein type [Nutrison Fibre®, Fresubin Energy Fibre®, Fresubin®, Supportan® (a special immunonutrition for cancer patients or patients with increased demands for omega-3 fatty acids), Fresubin Diabetes® (a diabetes-specific formula), Ensure®]; short peptide type (Peptison®); and amino acid type (Vivonex®). A pharmacoeconomic analysis was done based on defined daily dose methodology. Results Among hospitalized patients taking enteral nutrition, 34.8% received enteral nutrition alone, 30% concomitantly received parenteral nutrition, and 35.2% received enteral nutrition after parenteral nutrition. Combined use of the different formulas was observed in almost all hospitalized patients receiving enteral nutrition. In total, 61.5% of patients received triple therapy with Nutrison Fibre, Fresubin Diabetes, and Supportan. Number of defined daily doses (total dose consumed/defined daily dose, also called DDDs) of formulas in descending order were as follows: Nutrison Fibre, Fresubin Energy Fibre, Fresubin Diabetes > Supportan > Peptison, Ensure > Vivonex, Fresubin. The ratio of the cumulative DDDs for the three types of enteral nutrition was 35:2.8:1 (total protein type to short peptide type to amino acid type). Off-label use of Fresubin Diabetes was also observed, with most of this formula being prescribed for patients with stress hyperglycemia. Only 2.1% of cancer patients received Supportan. There were 35 cases of near misses in dispensing look-alike or sound-alike enteral nutrition formulas, and one adverse drug reaction in an elderly malnourished patient who did not receive vitamin K1-enriched enteral nutrition during treatment with cefoperazone. After 4 months of the trial intervention, off-label use of Fresubin Diabetes was no longer endorsed by the Drug and Therapeutics Committee for nondiabetic patients, and the proportion of this formula prescribed for patients with stress hyperglycemia decreased by 20%, with a 10-fold increase in the amount of Supportan prescribed for cancer patients. Near misses in dispensing look-alike or sound-alike enteral nutrition were successfully abolished, and no severe coagulation disorders occurred after prophylactic administration of vitamin K1-enriched enteral nutrition in elderly malnourished patients receiving cefoperazone. Conclusion This utilization study indicates that continuous quality improvement is necessary and that a Drug and Therapeutics Committee can play an important role in promoting rational and safe use of enteral nutrition. Appropriateness of this therapy still needs to be improved, especially in addressing the issues of non-evidence-based combined use of multiple enteral nutrition formulas, the relatively high rate of concomitant use of enteral and parenteral nutrition, off-label use of diabetes-specific Fresubin Diabetes, insufficient use of Supportan in cancer patients, and unnecessary use of Supportan in intensive care patients not suffering from cancer.

Expert consensus statements and summary of proceedings from the International Safety and Quality of Parenteral Nutrition Summit

Safety and quality of parenteral nutrition: Areas for improvement and future perspectives

Summary of Proceedings and Expert Consensus Statements from the International Summit "lipids in Parenteral Nutrition".

Summary of Proceedings and Expert Consensus Statements From the International Summit "Lipids in Parenteral Nutrition"

Prescribing Practice and Evaluation of Appropriateness of Enteral Nutrition in a University Teaching Hospital

Parenteral nutrition compatibility and stability: A comprehensive review

Safe and efficient practice of parenteral nutrition in neonates and children aged 0-18 years - The role of licensed multi-chamber bags

Quality and Safety Aspects of Infant Nutrition

Optimal nutrition therapy in paediatric critical care in the Asia-Pacific and Middle East: a consensus

Avoiding the use of long-term parenteral support in patients without intestinal failure: A position paper from the European Society of Clinical Nutrition & Metabolism, the European Society of Neurogastroenterology and Motility and the Rome Foundation for Disorders of Gut-Brain Interaction

[Expert consensus on clinical application of multi-chamber bag for parenteral nutrition (2022)].

Evaluation of Clinical Practice Guidelines for the Use of Supplementary Parenteral Nutrition in ICU Patients

ASPEN survey of parenteral nutrition access issues: How the system fails the patient

North American Summit on Aspiration in the Critically Ill Patient: Consensus Statement

Peripheral parenteral nutrition: A retrospective observational study to evaluate utility and complications

Parenteral nutrition compatibility and stability: Practical considerations

Expert consensus report on lipid mediators: Role in resolution of inflammation and muscle preservation

The Use of Multivitamin/Multimineral Supplements: A Modified Delphi Consensus Panel Report

Parenteral nutrition with standard solutions in paediatric intensive care patients

Parenteral nutrition at home/long-term parenteral nutrition

Role of pharmacists in providing parenteral nutrition support: current insights and future directions